• Je něco špatně v tomto záznamu ?

Inactivation of p53 and amplification of MYCN gene in a terminal lymphoblastic relapse in a chronic lymphocytic leukemia patient

K Stano-Kozubik, J Malcikova, B Tichy, J Kotaskova, M Borsky, V Hrabcakova, H Francova, I Valaskova, L Bourkova, J Smardova, M Doubek, Y Brychtova, S Pospisilova, J Mayer, M Trbusek

. 2009 ; 189 (1) : 53-58.

Jazyk angličtina Země Spojené státy americké

Typ dokumentu kazuistiky

Perzistentní odkaz   https://www.medvik.cz/link/bmc11006100
E-zdroje

NLK ScienceDirect (archiv) od 1993-01-01 do 2009-12-31

B-cell chronic lymphocytic leukemia (CLL) is an incurable disease with a highly variable clinical course. A proportion of patients eventually progress to a higher stage of malignancy. A recent association has been observed between the presence of aberrant somatic hypermutations in leukemic cells (hypermutations occurring outside of the immunoglobulin locus) and the transformation to a diffuse large B-cell lymphoma or prolymphocytic leukemia. In this study, we report on the rarely observed blastic transformation in a CLL patient who had previously been shown to harbor aberrant somatic hypermutations in the TP53 tumor-suppressor gene (Mol Immunol 2008;45:1525-29). The enzyme responsible, the activation-induced cytidine deaminase, was still active within the transformation, as evidenced by the ongoing class-switch recombination of cytoplasmic immunoglobulins. The transformation was accompanied by a complete p53 inactivation, as well as complex karyotype changes including prominent amplification of MYCN oncogene. Our case-study supports the view that the aberrant somatic hypermutation is associated with transformation of CLL to a more aggressive malignancy.

000      
03272naa 2200517 a 4500
001      
bmc11006100
003      
CZ-PrNML
005      
20240109133442.0
008      
110331s2009 xxu e eng||
009      
AR
040    __
$a ABA008 $b cze $c ABA008 $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Staňo Kozubík, Kateřina $7 xx0141563
245    10
$a Inactivation of p53 and amplification of MYCN gene in a terminal lymphoblastic relapse in a chronic lymphocytic leukemia patient / $c K Stano-Kozubik, J Malcikova, B Tichy, J Kotaskova, M Borsky, V Hrabcakova, H Francova, I Valaskova, L Bourkova, J Smardova, M Doubek, Y Brychtova, S Pospisilova, J Mayer, M Trbusek
314    __
$a Department of Internal Medicine-Hematooncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Jihlavska 20, 625 00 Brno, Czech Republic.
520    9_
$a B-cell chronic lymphocytic leukemia (CLL) is an incurable disease with a highly variable clinical course. A proportion of patients eventually progress to a higher stage of malignancy. A recent association has been observed between the presence of aberrant somatic hypermutations in leukemic cells (hypermutations occurring outside of the immunoglobulin locus) and the transformation to a diffuse large B-cell lymphoma or prolymphocytic leukemia. In this study, we report on the rarely observed blastic transformation in a CLL patient who had previously been shown to harbor aberrant somatic hypermutations in the TP53 tumor-suppressor gene (Mol Immunol 2008;45:1525-29). The enzyme responsible, the activation-induced cytidine deaminase, was still active within the transformation, as evidenced by the ongoing class-switch recombination of cytoplasmic immunoglobulins. The transformation was accompanied by a complete p53 inactivation, as well as complex karyotype changes including prominent amplification of MYCN oncogene. Our case-study supports the view that the aberrant somatic hypermutation is associated with transformation of CLL to a more aggressive malignancy.
650    _2
$a amplifikace genu $7 D005784
650    _2
$a lidé $7 D006801
650    _2
$a chronická lymfatická leukemie $x genetika $x patologie $x prevence a kontrola $7 D015451
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a jaderné proteiny $x genetika $7 D009687
650    _2
$a onkogenní proteiny $x genetika $7 D015513
650    _2
$a recidiva $7 D012008
650    _2
$a somatická hypermutace imunoglobulinových genů $x genetika $7 D027041
650    _2
$a nádorový supresorový protein p53 $x genetika $7 D016159
650    _2
$a financování organizované $7 D005381
655    _2
$a kazuistiky $7 D002363
700    1_
$a Malčíková, Jitka, $d 1979- $7 mub2011655946
700    1_
$a Tichý, Boris $7 xx0312236
700    1_
$a Kotašková, Jana $7 xx0128614
700    1_
$a Borský, Marek $7 xx0185903
700    1_
$a Hrabčáková, Viera $7 xx0127442
700    1_
$a Francová, Hana $7 xx0101487
700    1_
$a Valášková, Iveta $7 xx0082038
700    1_
$a Bourková, Ludmila $7 xx0124178
700    1_
$a Šmardová, Jana, $d 1961- $7 mzk2005304278
700    1_
$a Doubek, Michael, $d 1972- $7 mzk2004217554
700    1_
$a Brychtová, Yvona $7 xx0105542
700    1_
$a Pospíšilová, Šárka, $d 1969- $7 xx0101843
700    1_
$a Mayer, Jiří, $d 1960- $7 nlk20000083651
700    1_
$a Trbušek, Martin, $d 1969- $7 xx0101488
773    0_
$t Cancer genetics and cytogenetics $w MED00001039 $g Roč. 189, č. 1 (2009), s. 53-58
910    __
$a ABA008 $b x $y 2 $z 0
990    __
$a 20110414100056 $b ABA008
991    __
$a 20240109133439 $b ABA008
999    __
$a ok $b bmc $g 833719 $s 698190
BAS    __
$a 3
BMC    __
$a 2009 $b 189 $c 1 $d 53-58 $m Cancer genetics and cytogenetics $n Cancer Genet Cytogenet $x MED00001039
LZP    __
$a 2011-1B09/dkme

Najít záznam